NDAINJECTIONINJECTABLE
Approved
Mar 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
ARGATROBAN (argatroban) by Fresenius Kabi is thrombin inhibitors [moa]. First approved in 2015.
Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Argatroban is a direct thrombin inhibitor administered intravenously to prevent and treat thrombosis in patients with heparin-induced thrombocytopenia (HIT). It works by reversibly binding to the active site of thrombin, blocking clot formation without requiring antithrombin as a cofactor. This mechanism makes it a critical alternative for anticoagulation in HIT-positive patients who cannot tolerate heparin.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30%), indicating stable market position but limited growth runway for brand expansion teams.
Mechanism of Action
Thrombin Inhibitors
Pharmacologic Class:
Anti-coagulant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion
Started Nov 2010
9 enrolled
Coronary Artery Bypass Graft SurgeryPresence of Heparin/Platelet Factor 4 Antibody
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
Started Sep 2003
24 enrolled
ThrombocytopeniaThrombosis
Career Relevance
Argatroban positions you in a specialized, niche therapeutic area (HIT anticoagulation) with strong clinical significance but limited volume scaling. Careers on this product emphasize deep clinical expertise, prescriber relationships, and outcomes management over broad market penetration.
Worked on ARGATROBAN at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.